A Phase II, Multicenter, Single-Arm Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib for Adult Patients With Progressive Advanced Hepatocellular Carcinoma

Trial Profile

A Phase II, Multicenter, Single-Arm Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib for Adult Patients With Progressive Advanced Hepatocellular Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs Mipsagargin (Primary)
  • Indications Liver cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors GenSpera
  • Most Recent Events

    • 06 Jan 2016 According to a GenSpera media release, based on this trial the U.S. Food and Drug Administration has granted Orphan Drug designation for the treatment hepatocellular carcinoma.
    • 17 Mar 2015 Results presented as part of an overview of mipsgargin at 12th Annual BIO Asia International Conference, according to a GenSpera media release.
    • 10 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top